1. Inhibition of gastrin and gastric acid secretion by growth hormone release-inhibiting hormone;Bloom, SR, Mortimer; CH, Thorner; M.G.;Lancet,1974
2. Somatostatin inhibition of insulin and gastrin hypersecretion in pancreatic islet-cell carcinoma;Curnow, R.T.; Carey, R.M.; Taylor, A.; Johanson, A.; Murad, F.;N Engl J Med,1975
3. Somatostatininduced inhibition of hormone and target-organ secretions suggests new classification of hormone-secreting tumors (HST). International symposium on 'brain-gut axis: the New Frontier';Bonfils, S.; Rend, E.; Rigaud, D.; Chayvialle, J.A.; Rambaud, J.C.; Accary, J.P.;Florence; Abstract book p.25-26,1981
4. Lowering of basal and stimulated serum immunoreactive gastrin and secretion in patients with Zollinger-Ellison syndrome by somatostatin;Arnold, R.; Kobberling, J.; Track, N.S.; Creutzfeldt, W.;Acta Endocrinol,1975
5. Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue. Symptomatic and peptide responses;Wood, S.M.; Kraenzlin, M.W.; Adrian, T.E.; Bloom, SR;Gut,1985